Publications

Book Chapter

Yong –Ku Kim (editor) et al., ‘Understanding Depression …”- Springer Nature Singapore pvt ltd., Vol-2, Chapter-17, pp-235-249, 2018 with research scholar, Ms. Deepali Gupta.

Journal Publications

International

1. Kurhe Y, MaheshR, Devadoss T. Novel 5-HT3receptorantagonist QCM-4 attenuates depressive-like phenotype associated with obesity in high-fat-diet-fed mice. Psychopharmacology 2017; 234, 1165-1179. (Springer) (IF-3.87)

2. Mundra S, Thakur V, Bello A. M, Rathore S, Asad M, Wei L, Yang J, Chakka S. K, Mahesh R, Malhotra P, Mohmmed A, Kotra L. P. A novel class of Plasmodial ClpP protease inhibitors as potential antimalarial agents. Bioorganic & Medicinal Chemistry 2017; 25, 5662-5677 (IF-2.793)

3. Bhatt S, Mahesh R, Devadoss T, Jindal A. Neuropharmacological evaluation of a novel 5-HT3 receptor antagonist (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl) methanone (6g) on lipopolysaccharide-induced anxiety models in mice. Journal of Basic and Clinical Physiology and Pharmacology 2016, Volume 28, Issue 2, Pages 101– 106, ISSN (Online) 2191-0286, ISSN (Print) 0792-6855, (De Gruyter)

4. Bhatt S, Mahesh R, Jindal A, Devadoss T. Neuropharmacological and neurochemical evaluation of Nn-propyl-3- ethoxyquinoxaline-2- carboxamide (6n): a novel serotonergic 5-HT3 receptor antagonist for co-morbid antidepressant-and anxiolytic-like potential using traumatic brain injury model in rats. Journal of Basic and Clinical Physiology and Pharmacology 2016 Volume 28, Issue 2, Pages 93–100, ISSN (Online) 2191-0286, ISSN (Print) 0792-6855, (De Gruyter)

5. Kurhe Y, Mahesh R. Pioglitazone, a PPAR-ϒ agonist rescues depression associated with obesity using chronic unpredictable mild stress model in experimental mice. Neurobiology of Stress 2016; 3, 114-121. (Elsevier) (IF-1.0)

6. Bhatt S, Bagal SM, Butola S, Dhar AK, Mahesh R. Antidepressant-and anxiolytic-like effect of novel 5-hydroxytryptamine3 receptor antagonist 2-[4-(3-chlorophenyl) piperazin-1-yl]-1, 8-naphthyridine-3-carboxylic acid (7e)-: An approach using rodent behavioral antidepressant and anxiolytic test battery. International Journal of Nutrition, Pharmacology, Neurological Diseases 2016; 6, 81-89. (Medknow) (IF-0.6)

7. Gupta D, Prabhakar V, Radhakrishnan M. 5HT3 receptors: Target for new antidepressant drugs. Neuroscience & Biobehavioral Reviews 2016; 64, 311-325. (Elsevier) (IF-10.52)

8. Gupta D, Thangaraj D, Radhakrishnan M. A novel 5HT3 antagonist 4i (N-(3-chloro-2-methylphenyl)quinoxalin-2-carboxamide) prevents diabetes-induced depressive phenotypes in mice: Modulation of serotonergic system. Behavioral Brain Research 2016; 297, 41-50. (Elsevier) (IF-3.0)

9. Kurhe Y, Mahesh R. Ondansetron attenuates co-morbid depression and anxiety associated with obesity by inhibiting the biochemical alterations and improving serotonergic neurotransmission. PharmacologyBiochemistryandBehavior 2015;136, 107-116. (Elsevier) (IF-2.78)

10. Mundra S, Mahesh R. Pyridine-based microwave assisted one-pot synthetic protocol for the synthesis of ethyl 3-substituted-4-oxo-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylates. Research on Chemical Intermediates 2016; 42, 4207-4219 (Springer) (IF- 1.3)

11. Kurhe Y, Mahesh R. Mechanisms linking depression co-morbid with obesity: An approach for serotonergic type 3 receptor antagonists as novel therapeutic intervention. Asian Journal of Psychiatry 2015; 17, 3-9. (Elsevier) (IF-0.6)

12. Chakka S. K, Kalamuddin M, Mundra S, Mahesh R, Malhotra P, Mohmmed A, Kotra L. P. Identification of novel class of falcipain-2 inhibitors as potential antimalarial agents. Bioorganic & Medicinal Chemistry 2015; 23, 2221-2240 (Elsevier) (IF-3.3)

13. Gupta D, Mahesh R, Kurhe Y. Effect of a novel 5-HT3 receptor antagonist 4i, in corticosterone-induced depression-likebehavior and oxidative stress in mice. Steroids 2015; 96, 95-102. (Elsevier) (IF-2.71)

14. Jindal A, Mahesh R, Bhatt S. Etazolate, a Phosphodiesterase 4 enzyme inhibitor produces antidepressant-like effects by blocking the behavioral, biochemical, neurobiological deficits and histological abnormalities in hippocampus region caused by olfactory bulbectomy. Psychopharmacology, 2015; 232, 623-637. (Springer) (IF-3.396)

15. Jindal A, Mahesh R, Bhatt S. Type 4 phosphodiesterase enzyme inhibitor, rolipram rescues behavioral deficits in olfactory bulbectomy models of depression: Involvement of hypothalamic-pituitary-adrenal axis, cAMP signaling aspects and antioxidant defense system. Pharmacology Biochemistry and Behavior 2015; 132, 20-32. (Elsevier) (IF-2.78)

16. Kurhe Y, Mahesh R, Devadoss T. QCM-4, a 5-HT3 receptor antagonist ameliorates plasma HPA axis hyperactivity, leptin resistance and brain oxidative stress in depression and anxiety-like behavior in obese mice. Biochemical and Biophysical Research Communications 2015; 456, 74-79. (Elsevier) (IF-2.281)

17. Mundra S, Mahesh R. Evaluation of novel 1-(4-(substituted)piperazin-1-yl)-2-(phenylamino)ethanone derivatives as Falcipain-2 inhibitors. Journal of young Pharmacist 2015; 7, 96-105. (Elsevier) (IF-0.5)

18. Dhar AK, Mahesh R, Jindal A, Bhatt S. Piperazine analogues of naphthyridine-3-carboxamides and indole-2-carboxamides: Novel 5-HT3 receptor antagonists with antidepressant like activity, Archive Der Pharmazie 2015; 348, 34-45. (Wiley Online Library) (IF-1.39)

19. Kurhe Y, Mahesh R, Gupta D, Thangaraj D. Effect of (4a) a novel 5-HT3 receptor antagonist on chronic unpredictable mild stress induced depressive-like behavior in mice: an approach using behavioral tests battery. Journal of Basic and Clinical Physiology and Pharmacology, 2015; 26, 25-33. (De Gruter)(IF-0.6)

20. Mahesh R, Mundra S, Devadoss T. Design, synthesis and evaluation of 2-(4-(substituted benzoyl)-1,4-diazepan-1-yl)-N phenylacetamide derivatives as a new class of falcipain-2 inhibitors. Arabian Journal of Chemistry 2014; 20, 212-224. (Elsevier) (IF-2.7)

21. Gupta D, Mahesh R, Kurhe Y. Ondansetron, a 5HT-3 receptor antagonist reverses depression andanxiety-likebehavior in streptozotocin-induced diabetic mice: Possible implication of serotonergic system. European Journal of Pharmacology 2014; 744, 59-66. (Elsevier) (IF- 2.754)

22. Dhar AK, Mahesh R, Jindal A, Devadoss T, Bhatt S. Design, Synthesis, and Pharmacological Evaluation of Novel 2-(4-substituted piperazin-1-yl)1, 8 Naphthyridine 3-Carboxylic Acids as 5-HT3 Receptor Antagonists for the Management of Depression. Chemical Biology & Drug Design 2014; 84, 721-31. (Willey) (IF-2.50)

23. Kurhe Y, Mahesh R, Gupta D, Devadoss T. QCM-4, a serotonergic type 3 receptor modulator attenuates depression co-morbid with obesity in mice: An approach based on behavioral and biochemical investigations. European Journal of Pharmacology 2014; 740, 611-618. (Elsevier) (IF-2.75).

24. Kurhe Y, Mahesh R, Gupta, D. Ondansetron attenuates depression co-morbid with obesity in obese mice subjected to chronic unpredictable mild stress; an approach using behavioral battery tests. Metabolic Brain Disease 2014; 29, 701-710. (Springer) (IF-2.39).

25. Gupta, Deepali; Radhakrishnan, Mahesh; Kurhe, Yeshwant; Anxiolytic-like effects of alverine citrate in experimental mouse models of anxiety, European journal of pharmacology, 742 - 94-101 2014, Elsevier

26. Gupta D, Mahesh R, Kurhe Y, Thangaraj D, Prabhakar V, Kanade P. Antidepressant-like effects of6z,a novel5HT3 receptorantagonistin acute andchronicmouse models of depression. Acta Pharmacologica Sinica 2014; Accepted. (Nature) (2.496).

27. Kurhe Y, Mahesh R, Gupta D. Effect of a Selective Cyclooxygenase Type 2 Inhibitor Celecoxib on Depression Associated with Obesity in Mice: An Approach Using Behavioral Tests. Neurochemical Research 2014; 39:1395-1402. (Springer) (IF-2.55)

28. Bhatt S, Mahesh R, Jindal A, Devadoss T. Protective effects of a novel 5-HT3 receptor antagonist, N-n-butyl-3-methoxy quinoxaline-2-carboxamide (6o) against chronicunpredictable mild stress–induced behavioral changes and biochemical alterations. Pharmacology Biochemistry Behavior 2014; 122: 234-239. (Elsevier) (IF-2.75)

29. Bhatt S, Mahesh R, Jindal A, Devadoss T. Neuropharmacological Effect of Novel 5-HT3 Receptor Antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n) on Chronic Unpredictable Mild Stress-Induced Molecular and Cellular Response : Behavioural and BiochemicalEvidences. Pharmacological Reports 2014; 66: 804-810. (Elsevier) (IF-1.96)

30. Gupta D, Radhakrishnan M, Thangaraj D, Kurhe Y. Antidepressant and anti-anxiety like effects of 4i (3-Chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5-HT receptor antagonist in acute and chronic neurobehavioral rodent models. European Journal of Pharmacology 2014; 735: 59-67. (Elsevier) (IF-2.592)

31. Gupta D, Radhakrishnan M, Kurhe Y. Insulin reverses anxiety-like behavior evoked by streptozotocin-induced diabetes in mice. Metabolic Brain Disease, 2014; 29, 737-46. (Springer) (IF-2.33)

32. Gupta D, Kurhe Y, Radhakrishnan M. Antidepressant effects of insulin in streptozotocin induced diabetic mice: Modulation of brain serotonin system. Physiology & Behavior 2014; 129: 73-78. (Elsevier) (IF-3.1)

33. Mahesh R, Dhar AK, Jindal A, Bhatt S. Design, synthesis and evaluation of anti depressant activity of novel 2-methoxy 1, 8 naphthyridine 3-carboxamides as 5-HT3 receptor antagonists. Chemical Biology & Drug Design 2014; 83, 583-91. (Wiley Online Library) (IF-2.50)

34. Kurhe Y, Mahesh R, Gupta D, Thangaraj D. QCM-4 a novel 5-HT3 antagonist attenuates the behavioral and biochemical alterations on chronic unpredictable mild stress model of depression in Swiss albino mice. Journal of Pharmacy and Pharmacology 2014; 66, 122-32. (Wiley Online Library) (IF-2.03)

35. Bhatt S, Mahesh R, Jindal A, Devadoss T. Neuro-pharmacological evaluation of structurally novel 5-hydroxytryptamine type 3 receptor antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n) for its anxiolytic potential. International Journal of Nutrition, Pharmacology, Neurological Diseases 2013; 3, 383-387. (Medknow)

36. Jindal A, Mahesh R, Bhatt S. Etazolate rescues behavioral deficits in chronic unpredictable stress model: Modulation of hypothalamic-pituitary-adrenal axis activity and brain-derived neurotrophic factor level. Neurochemistry International 2013; 63, 465-75. (Elsevier) (IF- 2.659)

37. Mahesh R, Dhar AK, Jindal A, Bhatt S. 2-(4-substituted piperazin-1-yl)-1,8-naphthyridine-3-carboxylic acids: Novel 5-HT3 receptor antagonists with anxiolytic like activity in rodent behavioral models. Canadian Journal of Physiology and Pharmacology 2013; 91, 848-54. (NRC Research Press) (IF- 1.556)

38. Gautam BK, Jindal A, Dhar AK, Mahesh R. Antidepressant - Like Activity of 2-(4-phenylpiperazin-1-yl)-1, 8-naphthyridine-3-carboxylic acid (7a), a 5 -HT(3) Receptor Antagonist in Behaviour Based Rodent Models: Evidence for the Involvement of Serotonergic System. Pharmacology Biochemistry and Behavior 2013; 109, 91–97. (Elsevier) (IF-2.608)

39. Jindal A, Mahesh R, Bhatt S. Etazolate, a phosphodiesterase 4 inhibitor reverses chronic unpredictable mild stress-induced depression-like behavior and brain oxidative damage. Pharmacology Biochemistry and Behavior 2013; 105, 63-70. (Elsevier) (IF-2.608)

40. Jindal A, Mahesh R, Gautam B. Anxiolytic-like effect of linezolid, an oxazolidinone class antibiotic in experimental mouse models of anxiety. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2013; 40, 47-53. (Elsevier) (IF-3.552)

41. Jindal A, Mahesh R, Gautam B, Bhatt S, Pandey D. Antidepressant-like effect of etazolate, a cyclic nucleotidePhosphodiesterase4inhibitor –anapproach usingrodent behavioral antidepressanttestsbattery. EuropeanJournal of Pharmacology 2012;689, 125-131. (Elsevier) (IF-2.592)

42. Mahesh R, Devadoss T, Pandey DK, Dhar AK Sudali M, Mundra S, Bhatt S, Jindal A. Ligand-Based Design, Synthesis and Pharmacological Evaluation of 3-Methoxyquinoxalin-2-Carboxamides as Structurally Novel Serotonin Type-3 Receptor Antagonists. Archive Der Pharmazie 2012; 345, 687-94. (Wiley Online Library) (IF-1.54)
43. Mahesh R, Jindal A, Gautam B, Bhatt S, Pandey D. Evaluation of anti-depressant-like activity of linezolid, an oxazolidinone class derivative – An investigation using behavioral tests battery of depression. Biochemical and Biophysical Research Communications 2011; 409, 723-726. (Elsevier) (IF-2.40)

44. Mahesh R, Devadoss T, Pandey DK, Bhatt S. Discovery of newer anti-depressants from structurally novel 5-HT3 receptor antagonists: Design, synthesis and pharmacological evaluation of 3-ethoxyquinoxalin-2-carboxamides. Bioorganic & Medicinal Chemistry Letters 2011; 21, 1253-1256. (Elsevier) (IF-2.90)

45. Mahesh R, Devadoss T, Pandey DK, Yadav SK. Quinoxaline-2-Carboxamides: Synthesis and Pharmacological Evaluation as Serotonin Type-3 (5-HT3) receptor Antagonists. Journal of Enzyme Inhibition and Medicinal Chemistry 2011; 26, 610-615. (Informa Health Care) (IF-1.49)

46. Mahesh R, Dhar AK, Tarasasank, TVNV, Thirunavukkarasu S, Devadoss T. Citric acid: An efficient and green catalyst for rapid pot synthesis of quinoxaline derivatives at room temperature. Chinese Chemical Letters 2011; 22, 389-392. (Elsevier) (IF-1.21)

47. Pandey DK, Mahesh R, Kumar AA, Rao VS, Muralidharan A, Rajkumar R. A novel 5-HT2A receptor antagonist exhibits antidepressant-like effects in a battery of rodent behavioural assays: approaching early-onset antidepressants. Pharmacology Biochemistry and Behavior 2010; 94, 363-373. (Elsevier) (IF-2.75)

48. Devadoss T, Pandey DK, Mahesh R, Yadav SK. Effect of acute and chronic treatment with QCF-3 (4-benzyl pipirazin-1-yl) (quinoxalin-2-yl) methanone, a novel 5-HT3 receptor antagonist, in animal models of depression. Pharmacological Reports 2010; 62, 245-257. (Elsevier) (IF-1.96)

49. Mahesh R, Devadoss T, Pandey DK, Bhatt S, Yadav SK. Design, Synthesis and Structure Activity Relationship of Novel Quinoxalin-2-carboxamides as 5-HT3 Receptor Antagonists for the Management of Depression. Bioorganic & Medicinal Chemistry Letters 2010; 20, 6773-6776. (Elsevier) (IF-2.90)

50. Mahesh R, Pandey DK, Gautam B. Traumatic Brain Injury: Severity, Pathophysiology and Neurobehavioural Outcome. Pharmacologyonline Letters 2010; 1, 546-555. (IF-0.16)

51. Mahesh R, Pandey DK, Bhatt S, Gautam B. Depression Associated Disorders: Comorbidity, Neurobiological and Neurobehavioural Link. Pharmacologyonline Letters 2010; 1, 386-405. (IF-0.16)

52. Mahesh R, Pati D, Pandey DK, Kurdekar V, Jadhav HR. Anti-depressant-like activity of Mucuna Pruriens, a traditional Indian herb in animal models of depression. Pharmacologyonline Archives 2010; 1, 537-551. (IF-0.16)

53. Rajkumar R, Mahesh R. The auspicious role of the 5-HT3 receptor in depression: A probable neuronal target? Journal of Psychopharmacology 2010; 24, 455-469. (Sage Journals) (IF-3.37)

54. RajkumarR, PandeyDK, Mahesh R, RadhaR. 1-(m-Chlorophenyl) piperazineInduces Depressogenic-like Behaviour in Rodents by inhibiting the neuronal 5-HT2A receptors: Proposal of a Modified Rodent Anti-depressant assay.European Journal of Pharmacology 2009; 608, 32-41. (Elsevier) (IF-2.592)

55. Pandey DK, Yadav SK, Mahesh R, Ramamoorthy R. Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: A model of comorbid depression and anxiety. Behavioural Brain Research 2009; 205, 436-442. (Elsevier) (IF-3.32)

56. Pandey DK, Mahesh R. Depression: Current Therapy and novel Anti-depressant Drug Targets. Pharmacologyonline Letters 2009; 3, 993-1012. (IF-0.16)

57. Bhatt S, Mahesh R, Pandey DK, Pai KSR TAFI: A Potential Target for Fibrinolytic Drugs. Pharmacologyonline Letters 2009; 3, 770-781. (IF-0.16)

58. Ramamoorthy R, Mahesh R, Borah M. Anti-depressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models. Behavioural Pharmacology 2008; 19, 29-40. (Lippincott Williams and Wilkins) (IF-2.30)

59. Pandey DK, Ramamoorthy R, Mahesh R, Radha R. Depressant-like effects of Parthenolide in rodent behavioural anti-depressant test battery. Journal of Pharmacy and Pharmacology 2008; 60, 1643-1650. (Wiley Online Library) (IF-2.03)

60. Rajkumar R, Mahesh R. Assessing the Neuronal Serotonergic Target based Anti-depressant Stratagem: Impact of in vivo Interaction Studies and Knockout models. Current Neuropharmacology 2008; 6, 215-234. (Bentham Science)(IF-3.08)

61. Mahesh R, Rajkumar R, Minasri B, Perumal V. Potenatial anti-depressants; Pharmacology of 2 (4-methyl piperazine -1yl) -1, 8 naphthyridine -3-carbonitrile in rodent behavioural models. Pharamzie 2007; 63, 23-30. (Govi-Verlag) (IF-0.96)

62. Mahesh R, Perumal VR, Pandi, PV. Microwave–assisted solvent–free synthesis of 3-[(4-substitutedpiperazin-1-yl) alkyl] imidazo [2, 1-b][1,3] benzothiazol-2 (3H)-ones as Serotonin3 (5-HT3) receptor antagonists. Pharmazie 2005; 60, 411-414. (Govi-Verlag) (IF-0.96)

63. Mahesh R, Perumal VR, Pandi, PV. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods. Pharmazie 2005; 60, 83-96. (Govi-Verlag) (IF-0.96)

64. Mahesh R, Perumal VR, Pandi PV. Microwave assisted synthesis of 2- (4-substituted piperazin-1-yl)-1,8-naphthyridine-3-carbonitrile as a new class of serotonin 5-HT3 receptor antagonists. Bioorganic Medicinal Chemistry Letter 2004; 14, 5179-5181. (Elsevier) (IF-2.90)

65. Mahesh R, Perumal V, Pandi PV. Pharmacophore Based Synthesis of 3-Chloroquinoxaline-2-carboxamides as Serotonin3 (5-HT3) Receptor Antagonist. Biological and Pharmaceutical Bulletin 2004: 27, 1403-1405. (The Pharmaceutical Society of Japan) (IF-1.849)

66. Bajaj S, Mahesh R. Converged avenues: depression and Alzheimer’s disease–shared pathophysiology and novel therapeutics. Molecular Biology Reports. 2024; 51(1):225.

National

66. Kurhe Y, Mahesh R (2017). Ondansetron ameliorates depression associated with obesity in high fat diet fed experimental mice: an investigation based on the behavioral, biochemical and molecular approach. Indian J Pharmacol 2017;49,290-296. (Medknow) (IF-0.68)

67. Mundra S, Mahesh R. Insignificant in vitro falcipain-2 inhibitory activity of novel 2-(4-(substituted benzoyl) piperazine-1-yl)-N-phenylacetamide derivatives. Journal of Pharmaceutical Negative Results 2015; 6, 20-26. (Medknow)

68. Prabhakar V, Gupta D, Kanade P, Radhakrishnan M. Diabetes-associated depression: The serotonergic system as a novel multifunctional target. Indian Journal of Pharmacology 2015; 47, 4-10. (Medknow) (IF-0.68)

69. Kurhe Y, Mahesh R, Devadoss T, Gupta D. Antidepressant-like effect of a novel 5-HT3 receptor antagonist N-(benzo [d] thiazol-2-yl)-3-ethoxyquinoxalin -2-carboxamide 6k using rodents behavioral battery tests.Journal of Pharmacology & Pharmacotherapeutics 2014; 5, 197-202. (Medknow) (IF-0.68)

70. Kurhe YV, Mahesh R, Thangaraj D, Gupta D. Anti-anxiety effect of a novel 5-HT3 receptor antagonist N-(benzo[d]thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide (6k)using battery tests for anxiety in mice. Indian Journal of Pharmacology 2014; 46, 100-104. (Medknow) (IF-0.68)

71. Bhatt S, Mahesh R, Jindal A, Devadoss T, Dhar AK. Neuropharmacological evaluation of a novel 5-HT3 receptor antagonist (6g) on chronic unpredictable mild stress-induced changes in behavioural and brain oxidative stress parameters in mice. Indian Journal of Pharmacology 2014; 46, 191-196. (Medknow) (IF-0.58)

72. Jindal A, Mahesh R, Bhatt S. Anxiolytic-like effect of etazolate, a type 4 phosphodiesterase inhibitor in experimental models of anxiety. Indian Journal of Experimental Biology 2013; 51, 444-449. (NISCAIR) (IF-1.195)

73. Bhatt S, Mahesh R, Jindal A, Devadoss T. Anti-depressant like activity of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (6o) a 5-HT3 receptor antagonist. Indian Journal of Experimental Biology 2013; 51, 435-443. (NISCAIR) (IF-1.195)

74. Bhatt S, Mahesh R, Jindal A, Devadoss T. Anxiolytic-like effect of N-n-butyl-3-methoxyquinoxaline-2-carboxamide (6o) in experimental mouse models of anxiety. Indian Journal of Experimental Biology 2013; 51, 510-514. (NISCAIR) (IF-1.195)

75. Bhatt S, Mahesh R, Jindal A, Devadoss T. Antidepressant- like effect of novel 5-HT3 receptor antagonist N-n-butyl-3- ethoxyquinoxalin-2-carboxamide (6p)- an approach using rodent behavioral antidepressant tests battery. Indian Journal of Pharmacology 2013; 45, 348-353. (Medknow) (IF-0.58)

76. Kurhe YV, Mahesh R, Gupta D, Thangaraj D. Effect of a novel 5-HT3 receptor antagonist 3-methoxy-n-p-tolylquinoxalin-2-carboxamide (QCM-4) on the acute and chronic rodent models of depression. International Journal of Pharmacy and Pharmaceutical Sciences 2013; 5, 567-573. (Academic Sciences)(IF-0.91)

77. Gupta D, Radhakrishnan M, Bhatt S, Kurhe Y. Role of Hypothalamic-pituitary-adrenal-axis in Affective Disorders: Anti-depressant and Anxiolytic Activity of Partial 5-HT1A Agonist in Adrenalectomised Rats.Indian Journalof Psychological Medicines 2013; 35, 290-8. (Medknow)

78. Bhatt S, Mahesh R, Devadoss D, Jindal A. Anxiolytic-Like Effect of (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl)methanone (6g) in Experimental Mouse Models of Anxiety. Indian Journal of Pharmacology 2013; 45, 248-251. (Medknow) (IF-0.58)

79. Mahesh R, Bhatt S, Devadoss T, Jindal AK, Gautam BK, Dhar AK, Pandey DK. Anti-depressantLike EffectofNovel 5-HT3 Receptor Antagonist, (4-benzylpiperazin-1-yl)(3-methoxyquinoxalin-2-yl)methanone (6g) in Acute and Chronic Animal Models of Depression. Indian Journal of Pharmaceutical Education and Research, 2013; 47, 71-81. (APTI) (IF-0.15)

80. Kumar B, Jindal A, PandeyDK, Bhatt S, Devadoss D, Mahesh R. Antidepressant and anxiolytic-like effects of 4n, a novel 5-HT3 receptor antagonist using behaviour based rodent models. Indian Journal of Experimental Biology 2012; 50, 625-632. (NISCAIR) (IF-1.195)

81. Mahesh R, Kumar B, Jindal A, Bhatt, S, Devadoss T, Pandey DK. Antidepressant- like activity of (4-phenylpiperazin-1-yl) (quinoxalin-3-yl) methanone (4a), a Novel5-HT3 receptor antagonist: An investigation in behaviour-based rodent models of depression. Indian Journal of Pharmacology, 2012; 44, 560-565. (Medknow) (IF-0.58)

82. Jindal A, Mahesh R, Gautam B, Bhatt S, Pandey D. Evaluation of anti-diabetic activity of methanolic extract from the bark of Atalantia monophylla (Linn.) in alloxan-induced diabetic mice. International Journal of Green Pharmacy 2012; 6, 133-137. (Medknow)

83. Mahesh R, Bhatt S, Devadoss T, Jindal AK, Gautam BK, Pandey DK. Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n-propyl-3-ethoxyquinoxaline-2-carboxamide (6n). Journal of Young Pharmacist 2012; 4, 235-244. (Elsevier)

84. Jindal A, Mahesh R, Singh K, Bhatt S, Gautam, B; Pandey D. Ameliorative Effect of Wortmannin and Rapamycin Treatment on Obesity Markers in High Fat Diet feed rats. Indian Journal of Pharmaceutical Education and Research 2011; 45, 333-338. (APTI) (IF-0.15)

85. Mahesh R, Pandey DK, Bhatt S, Gautam B. Anti-depressant like Effect of Pimozide in Acute and Chronic Animal Models of Depression. Indian Journal of Pharmaceutical Education and Research 2011; 45, 46-53. (APTI) (IF-0.15)

86. Gupta D, Devadoss T, Bhatt S, Gautam B, Jindal A, Pandey D, Mahesh R. Antidepressant like effect of a novel serotonin type-3 (5HT3) receptor antagonist in rodent models of depression. Indian Journal of Experimental Biology, 2011; 49, 619-626. (NISCAIR) (IF-1.195)

87. Chaudhary S, Mahesh R, Gautam B, Jindal A, Bhatt S. Serotonin 5-HT6 Receptor: A Potential Target For Cognition. International Research Journal of Pharmacy 2010; 1, 7-18. (Moksha Publishing House)

88. Mahesh R, Aprna A, Ramakrishnan V, George J, Pandey DK. Demographic Study On Disease Prevalence And Their Treatment Pattern In A Local Hospital Of A Semi-Urban Community.InternationalJournalofResearchin Ayurveda and Pharmacy2010; 1,569-564. (Moksha Publishing House)

89. Mahesh R, Devadoss T, Pandey DK, Baldev G, Jindal A, Shvetank B. Depression Associated Comorbid Cardiovascular And Metabolic Complications International. Journal of Research in Ayurveda and Pharmacy 2010; 1, 23-32. (Moksha Publishing House)-Invited article

90. Mahesh R, Sharma P, Gautam BK, Bhatt S, Pandey DK. Antidepressant-like activity of cannabinoid type-1 receptor antagonist, rimonabant: behavioural investigation in animal model of depression. International Journal of Pharma and Biosciences 2010; 1, 1-13. (Indian Science)-Invited article

91. Mahesh R, Pandey DK, Katiyar S, Kukade G, Viyogi S, Rudra A. Effect of Anti-depressants on neuro-behavioural consequences following impact accelerated traumatic brain injury in rats. Indian Journal of Experimental Biology 2010; 48, 466-473. (NISCAIR) (IF-1.195)

92. PandeyDK, Pati D, Joshi A, Mahesh R. Chronic Unpredictable Stress: Possible Animal Model of Comorbid Depression. International Journal of Preclinical and Pharmacy Research 2010; 1, 54-65. (Indian Science)-Invited article

93. Mahesh R, Shruti V, Pandey DK, Yadav SK. Evaluation of Anti-depressant and Analgesic- Like Activity of Ondansetron in Rodents model of Comorbid Pain and Depression. Indian Journal of Pharmaceutical Education and Research 2010; 44, 160-170. (APTI) (IF-0.15)

94. Gautam BK, Rana M, Pandey DK, Mahesh R, Singh M. The Possible Role of PI3K/Akt Pathway in Partial Abdominal Aortic Constriction (PAAC) Induced Pathological Cardiac Hypertrophy. International Journal of Pharma Recent Research 2009; 1, 1-11.

95. Rajkumar R, Mahesh R. Behavioural Investigation of Ondansetron in Rodent Models: Are 5-HT3 Receptors Potential Neuronal Targets of Depression? AAPS J 2007; 9(S2), Abstract no M1160

96. Mahesh R, Perumal VR. Microwave-induced Mannich reaction– Synthesis of some Mannich derivatives of p-aminophenol. Indian Journal of Chemistry 2004; 43, 1012-1014. (NISCAIR)

Conference Publications

International

1. Kurhe Y, Mahesh R, Thangaraj D. Mechanisms linking depression associated with obesity through serotonergic modulation in experimental mice. Society for Neuroscience (SfN) 46th Annual Meeting, Neuroscience 2016, Nov 12-16, 2016, San Diego, California, United States.

2. Gupta D, Mahesh R. 6z, a novel 5HT3 receptor antagonist reverses depression-like behavior in streptozotocin-induced diabetic mice by normalizing serotonin deficiency and HPA-axis hyperactivity. 14th Meeting of the Asian Pacific Society for Neurochemistry, Aug 27-30, 2016, Kuala Lumpur, Malaysia.

3. Kurhe Y, Mahesh R, Thangaraj D. Serotonergic type 3 receptor antagonist (4-phenylpiperazin-1-yl) (quinoxalin-2-yl) methanone (4a) attenuates depression co-morbid with obesity by promoting serotonergic neuromodulation and reversing insulin resistance in experimental mice. IBRO/APRC Varanasi School (Molecular Advancements in Neurobiology), Sept 5-20, 2015, Varanasi, India.

4. Gupta D, Mahesh R. 4i (N-(3-Chloro-2-methylphenyl) quinoxalin-2-carboxamide), a novel 5HT3 antagonist, reverses diabetes-induced depressive phenotype. 25th ISN-APSN Joint Biennial Meeting organized by Australasian Society for Neuroscience (ANS), August 23-27, 2015, Cairns, Australia.

5. Gupta D, Mahesh R, Kurhe Y, Thangaraj D. Antidepressant-like effects of EQC-34,a novel 5HT-3 receptor antagonist in neurobehavioral mouse model of depression. International Conference on Pharmacy and Pharmacology (ICPP)-2014, 26-27 September, 2014, London, UK.

6. Kurhe Y, Mahesh R, Gupta D, Thangaraj D. Antidepressive-Like Effect Of A Novel 5-HT3 Receptor Antagonist (4a) Against Depression Co-Morbid With Obesity In Mice Subjected To Chronic Stress. FENS Forum of Neuroscience, 5-9 July, 2014, Milan, Italy.

7. Mahesh R, Mundra S, Mohammed A. Design and synthesis of falcipain-2 Inhibitor’s as a potential Antimalarial Agents. Chemical Biophysics Symposium, 21-23 April, 2013, Toronto, Canada.

8. Mahesh R, Mundra S. Design, Synthesis of Novel Antimalarial agents. Biological Therapeutics Symposium, 2-3 May 2013, University of Toronto, Toronto-Canada.

9. Mahesh R, Mundra S. Fluorimetric assay for falcipain-2 activity using Victor multi-label counter. Biomedical Engineering & Science Technology (BEST) Symposium at St. Michael’s Hospital, 13 June, 2013, Toronto-Canada.

10. Radhakrishnan Mahesh, Jayashree Mahesh, “The Post-Covid Era of Higher Education in India: Trends, Challenges, and Strategic Insights form a Global Perspective”, “6^th Annual Conference of Aston India Centre for Applied Research (AICAR): India and the VUCA World” at Aston Business School, Birmingham, United Kingdom, on 1-2 September, 2024.

11. Bajaj, Shivanshu; Mahesh, Radhakrishnan; Department of Pharmacy, Birla Institute of Technology and Science (BITS), Pilani campus. “Escitalopram and Galantamine in Combination Modulate Alpha-7 Nicotinic Receptor and Ameliorate Unpredictable Chronic Mild Stress-Induced Depression-Like Behaviour in Mice”. FENS FORUM- June 2024, International Neuroscience Conference, Vienna, Austria.

National

12. Sushil Kumar Yadav, R Mahesh, Vishal Saxena Milk derived peptide induced histopathological changes in rat bone. International Conference on Life Science Research & its Interface with Engineering and Allied Sciences (LSRIEAS 2018) organized at BITS, Pilani, Pilani Campus, Nov 1-3, 2018. ( Best Poster Award)

13. Dahitule Gauri Chandrakant, Radhakrishnan Mahesh, Telescopic Forecasting And Preventive Strategies For Alzheimer’s Disease, International Conference on Frontiers in Neuroscience and Neurochemistry: Dynamic Challenges and Approaches, Society for Neurochemistry India (SNCI), Jamia Hamdard, Delhi, 10-12 Oct., 2019

14. Sushil Kumar Yadav, R Mahesh, Vishal Saxena Separation and Analysis of Beta Casein Variants from Cow Milk and their Application in Solubility Enhancement of Poorly Water Soluble Drug. “8th Annual International Conference on Dissolution Science and Applications” - Disso India 2019 organized at NIPER-SAS Nagar, September 11 - 13, 2019.

15. Sushil Kumar Yadav, R Mahesh, Vishal Saxena Development of new analytical method for the analysis of β- casein variants in cattle from Pilani region. International Conference on Challenges in Drug Discovery and Delivery (ICCD3-2017), organized at BITS, Pilani, Pilani Campus, March2-4, 2017

16. Sushil Kumar Yadav, R Mahesh, Vishal Saxena Epidemiological study of beta-casein alleles. Golden Jubilee Concluding Celebrations & Annual Confrence of Indian Pharmacological Society (IPSCON-2017), organized by Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM’S NMIMS, Mumbai, India, Feb 15-17, 2018

17. Kurhe Y, Mahesh R. Ondansetron ameliorates depression associated with obesity in high fat diet fed experimental mice: an investigation based on the behavioral, biochemical and molecular approach. 49th Annual Conference of Indian Pharmacological Society (IPSCON-2016) on October 20-23, 2016, PGIMER Chandigarh, Punjab, India.

18. Mundra S, Mahesh R. Design, Synthesis and Structure Activity Relationships of Novel Peptidomimetics as Potential Anti-malarial Agents. 49th Annual Conference of Indian Pharmacological Society (IPSCON-2016) on October 20-23, 2016, PGIMER Chandigarh, Punjab, India.

19. Mundra S, Mahesh R. Identification of novel class of falcipain-2 inhibitors as potential anti-malarial agents. Organic Chemistry in Sustainable Development: Recent advantages and future challenges (OCSD-2016), August 29-30, 2016, BITS Pilani, Pilani Campus, Pilani, Rajasthan, India.

20. Kurhe Y, Mahesh R. High fat diet fed obese rats injected with exogenous corticosterone: an animal model to study depressive-phenotypes associated with obesity. DBT, ICMR and APTI Sponsored Two Days National Conference on “Contemporary Technologies in Drug Delivery and Envisaged Future Trends” on August 12-13, 2016 at Geetanjali Institute of Pharmacy, Geetanjali University, Udaipur, Rajasthan, India.

21. Bhatt S, Mahesh R, Devadoss T, Jindal A. Pharmacological profiling of quinoxalin derivative (6g), a novel serotonergic 5-HT3 receptor antagonist for its antidepressant-and anxiolytic-like activity in traumatic brain injury model in rats. IPC Conference, December 19-21, 2015, JSS University, Mysore, India.

22. Mundra S, Mahesh R. Evaluation of novel class of falcipain-2 inhibitors as potential anti-malaria agents. New Frontiers In Chemistry-From Fundamentals To Applications (NFCFA 2015), December 18-19, 2015, BITS Pilani, Goa Campus, Goa, India.

23. Mundra S, Mahesh R. Design, Synthesis and careening of falcapin-2 inhibitors as novel anti-malarial agents. 2nd NirmaInstitute ofPharmacyInternationalConference, NIPICON January 23-25, 2014, Ahmedabad, India.

24. Mahesh R, Jindal A, Bhatt S. Etazolate rescues behavioral deficits in chronic unpredictable stress models of depression by the modulation of HPA axis, BDNF signaling andantioxidant defence system: possible mechanism(s) of neuroprotection. International Conference on Recent Advances in Molecular Mechanisms of Neurological Disorders, 21-23rd February 2013, AIIMS New Delhi.

25. Mahesh R, Bhatt S, Devadoss T, Jindal A. Neuropharmacological effect of (4-benzylpiperazin-1-yl) (3-methoxyquinoxalin-2-yl) methanone (qcm-15), a potential 5-ht3 receptor antagonist on chronic unpredictable mild stress-induced changes in behavior and brain oxidative stress in mice. International Conference on Recent Advances in Molecular Mechanisms of Neurological Disorders, 21-23rd February 2013, AIIMS New Delhi.

26. Mahesh R, Dhar AK, Jindal A Bhatt S. 2-(4-substitutedpiperazin-1-yl)-1,8-naphthyridine-3-carboxylic acids: novel 5-HT3 receptor antagonists as potential anxiolytics. International Conference on Recent Advances in Molecular Mechanisms of Neurological Disorders, 21-23rd February 2013, AIIMS New Delhi.

27. Muthu VS, Mahesh R, Jindal A. Design, synthesis and pharmacological evaluation of novel Phosphodiesterases-4 inhibitors as potential anti-depressants. International Conference on Recent Advances in Molecular Mechanisms of Neurological Disorders, 21-23rd February 2013, AIIMS New Delhi.

28. Gupta D, Mahesh R, Kurhe Y. Diabetes associated depression: ondansetron, as an antidepressant for streptozotocin induced diabetes associated depression in mice. Journal of Diabetes and Metabolism, OMICS Group Conferences, 3: 8, 133, 24-26th September 2012, Hyderabad.

29. Gupta D, Mahesh R, Bhatt S, Devadoss T. Antidepressant like activity of buspirone and role of HPA axis dysregulation in depression. National conference on pharmacy and pharmaceutical sciences-from bench to market. Pharmanext (AIPER), 28-29th April 2012, Madhya Pradesh.

30. Mahesh R, Bhatt S, Panjawani R, Devadoss T, Jindal A. Neuro-pharmacological evaluation of novel serotonin type-3 (5-HT3) receptor antagonists qcm-15, qcm-16, qct-16 & qct-22 (quinoxaline derivatives) for their anxiolytic potential. Indian Pharmaceutical Association Convention, 17-18th March 2012, Manipal.

31. Mahesh R, Mundra S, Devadoss T, Dhar AK, Sudali MV. Design and synthesis of pyrimidine scaffold for their kinase inhibitor activity. National conference of Pharmanext 19-20 February 2012, Aligarh.

32. Mahesh R, Dhar AK, Jindal A, Muthu VS, Mundra S. Design, synthesis and pharmacological evaluation of Novel 2-(4-substituted piperazine 1-yl)-1,8-naphthyridine 3-carboxylic acids as 5-HT3 receptor antagonists for the management of depression. Indian Pharmaceutical Association Convention, 17-18th March 2012, Manipal.

33. Mahesh R, Mundra S, Dhar AK, Sudali MV. Design and synthesis and screening of falcipain-2 Inhibitors. National conference ‘’Molecular Diagnostics: Challenges vis-à-vis Growth Potential“- Organized by Department of Biotechnology and Confederation of Indian Industries. 8 June 2012, Delhi.

34. Mahesh R, Sudali MV, Murugesan S, Dhar AK, Mundra S, Jindal A. "Design and docking study of 4-benzyl-3-oxo-3,4-dihydroquinoxaline-2-carboxamide analogues as phosphodiestrase-iv (PDE-IV) inhibitors". Indian Pharmaceutical Association (IPA) Convention 17-18 March, 2012, Manipal.

35. Mahesh R, Kumar B, Jindal A, Pandey D, Bhatt S, Devadoss T. Antidepressant like activity of (4-phenylpiperazin-1-yl) (quinoxalin-3-yl) methanone (4a), a novel 5 HT3 receptor antagonist: An investigation in behaviour-based rodent models. Indian Pharmacological Society Conference, 19-21th December 2011, Manipal (Oral Presentation).

36. Mahesh R, Jindal A, Kumar B, Bhatt S, Pandey D. Rolipram, a phosphodiesterase 4 (PDE4) enzyme inhibitor as a potential anti-depressant: An investigation using behavioral tests battery of depression. Indian Pharmacological Society Conference 19-21th December 2011, Manipal.

37. Mahesh R, Dhar A, Singh S, Jindal A, Sharma A, Bhatt S. Evaluation of antianxiety like activity of 2-(-4-phenylpiperazine-1-yl) 1.8-Naphthridine-3-carboxylic acid(7a) A serotonin type-3(5-HT3) receptor antagonist: An investigation using behavioural test battery of anxiety. Indian Pharmacological Society Conference 19-21th December 2011, Manipal.

38. Mahesh R, Dhar A, Sharma A, Jindal A, Singh S, Kumar B. Behavioral investigation on antidepressant like activity of 2-(-4-phenylpiperazine-1-yL) 1,8-Naphthlidine-3-carboxylic acid(7a)Anovel serotonin type-3(5-HT3)receptorantagonist:for comorbid depression with cancer chemotherapy induced nausea and vomiting(CINV). Indian Pharmacological Society Conference 19-21th December 2011, Manipal.

39. Mahesh R, Srinivasrao B, Devadoss T, Jindal A, Bhatt S, Kumar B. Studies on the analgesic and anti-inflammatory activity of n-[2-(1h-indol-3-yl)ethyl]quinoxalin-2-caboxalicacid (qcf-20), a novel serotonin type-3 (5-ht3) receptor antagonist. Indian Pharmacological Society Conference 19-21th December 2011, Manipal.

40. Bhatt S, Panjwani R, Devadoss T, Gautam BK, Jindal A, Mahesh R. To evaluate a novel 5 HT3 receptor antagonist 3-Ethoxy-N-Propylquinoxaline-2-carboxamide (EPQC) for its anti-depressant and anxiolytic potential. APTICON 7-9th October 2011, Moga, Punjab.

41. Gupta D, Mahesh R, Bhatt S, Devadoss T. Pharmacological evaluation of novel serotonin type-3 (5HT3) receptor antagonist for comorbid depression and anxiety in rodent models of comorbid disorder. Indian Pharmaceutical Association Convention, 19-20th February 2011, Indore.

42. Mahesh R, Pandey D, Pinky Sharma. 1(m- chlorophenyl) Pipirazine (mCPP) induces depressogenic- like behaviour in rodent by stimulating the neuronal 5-HT receptor as a potential rodents Anti-depressant assays. Pharmanext Conference, 18-19th September 2010, Jaipur.

43. Mahesh R, Bhatt S , Gautam B, Pandey D, Devadoss T. Evaluation of novel 5-HT3 antagonist as a potential anti-depressant in comorbid condition. Pharmanext Conference, 18-19th September 2010, Jaipur.

44. Mahesh R, Gautam B, Pandey D, Bhatt S, Ramamoorthy R. Hyposerotonergic consequences of parthenolide in a battery of rodents behavioural Assays of depression. Pharmanext Conference, 18-19th September 2010, Jaipur.

45. Mahesh R, Jindal A, Kurdekar A, Jhadav H, Bhatt S, Gautam BK, Pandey DK. Evaluation of Anti-oxidant, Analgesic and Anti-inflammatory activity of Methanolic Bark extract of Atalantia monophylla. Indian Pharmacological Society Conference, 14-16th December 2010, Hyderabad.

46. Mahesh R, Gumpally C, Bhatt S, Thangaraj Devadoss, Dilip Pandey, Gautam B, Ankur Jindal. Evaluation of novel sertonergic type-3 receptor antagonist quinoxalin-2-carboxylic acid derivative (qct-22) for their antidepressant potential. Indian Pharmacological Society Conference 14-16th December 2010, Hyderabad.

47. Mahesh R, Chaudhary S, Bhatt S, Devadoss T, Pandey D, Gautam B, Jindal A. Preclinical evaluation of quinoxalin-2-carboxylic acid derivative (qct-16), a novel sertonergic modulator for their anti-depressant potential. Indian Pharmacological Society Conference, 14-16th December 2010, Hyderabad.

48. Mahesh R, Modak N, Bhatt S, Devadoss T, Pandey D, Gautam B, Jindal A. Novel Quinoxaline Derivative: A Potential Anti Depressant For Treatment Resistant Depression. Indian Pharmacological Society Conference, 14-16th December 2010, Hyderabad.

49. Mahesh R, Bhatt S, Devadoss T, Gautam B, Soni P, Gumpally C, Jindal A, Pandey D. Pharmacological profiling of quinoxalin-2-carboxylic acid derivative (qcm-16), a novel sertonergic modulator for its anti-depressant potential. Indian Pharmacological Society Conference, 14-16th December 2010, Hyderabad.

50. Mahesh R, Bhatt S, Devadoss T, Gautam B, Jindal A, Pandey D. Qcm-13(n-cyclohexyl-3-methoxyquinoxalin-2carboxamide) a novel antidepressant; pharmacological evaluation of the potential serotonin type 3 (5-ht3) receptor antagonist. Indian Pharmacological Society Conference, 14-16th December 2010, Hyderabad. a novel antidepressant; pharmacological evaluation of the potential serotonin type 3 (5-ht3) receptor antagonist. Indian Pharmacological Society Conference, 14-16th December 2010, Hyderabad.

51. Mahesh R, Pandey D, Sharma P. 1(m- chlorophenyl) Pipirazine (mCPP) induces depressogenic- like behaviour in rodent by stimulating the neuronal 5-HT receptor as apotential rodents Anti-depressant assays. Pharmanext Conference, 18-19th September 2010, Jaipur.

52. Mahesh R, Pandey D, Devadoss T. Effect of acute and chronic treatment with QCF-3 (4-benzyl pipirazin-1-yl) (quinoxalin-2-yl) methanone, a novel 5-HT3 receptor antagonist, in animal models of depression. Indian Pharmacological Society Conference, 10-12th December 2009, Kolkata.

53. Mahesh R, Baldev G, Shvetank, Bhatt, Pandey D. Pimozide 5-HT7 / D2 antagonist evaluation in acute and Chronic model of depression. Indian Pharmacological Society Conference, 10-12th December 2009, Kolkata.

54. Mahesh R, Devadoss T,Pandey DK, Yadav S. Synthesis, 5-HT3 antagonist and anti-depressant evaluation of novel quinoxaline derivatives. National Conference on Emerging Trends In Life Sciences Research, 6-7th March 2009, BITS Pilani, Rajasthan, India.

55. Pandey DK, Mahesh R. Antidepressant-like effect of serotonin 2a (5-HT2a) receptor antagonist in rodents: approaching to novel quick-onset antidepressants. National Conference on Emerging Trends In Life Sciences Research, 6-7th March, 2009, BITS Pilani, Rajasthan, India.

56. Mahesh R, Bhatt S, Devadoss T, Joshi A, Pandey DK, Yadav S. Evaluation of novel serotonin type 3 (5-HT3 ) receptor antagonist for their anti-depressant like Activity. APTICON, 3-4th October 2009, Jodhpur, Rajasthan.

57. Mahesh R, Sharma P, Pandey DK, Yadav S. Rimonabant : A potential drug for comorbidobesityand depression. APTICON3-4th October 2009,Jodhpur,Rajasthan.

58. Mahesh R, Pati D, Pandey DK, Kurdekar V, Jadhav HR. Mucuna Pruriens: A traditional Indian anti-parkinsonian herb with potent anti-depressant activity. APTICON 3-4th October 2009, Jodhpur, Rajasthan.

59. Mahesh R, George J, Vidya R, Pandey DK, Jain RK. Alok T. Demographic study on disease prevalence and their treatment pattern in a local hospital of semi urban community. APTICON, 3-4th October 2009, Jodhpur, Rajasthan.

60. Mahesh R, Devadoss T, Pandey DK, Yadav S. 3-ethoxyquinoxalin-2-carboxamode: A new series of potential 5-HT3 receptor antagonist for the management of depression. APTICON, 3-4th October 2009, Jodhpur, Rajasthan.

61. Pandey DK, Mahesh R, Yadav SK. Neuro-Psychiatric Sequelae of Depression and Anxiety Following Impact Accelerated Traumatic brain Injury in Rats: A Model for Comorbidity. International Symposium on Pharmaceutical and Biomedical Analysis, 1-4th March 2009, Agra India.

62. Aparna M, Mahesh R, Pandey DK, Agarwal R, Sarkar S. Neuroprosthetics as Non-Pharmacological Intervention Techniques. International Symposium on Pharmaceutical and Biomedical Analysis, 1-4th March 2009, Agra India. Intervention Techniques. International Symposium on Pharmaceutical and Biomedical Analysis, 1-4th March 2009, Agra India.

63. Pandey DK, Mahesh R, Rajkumar R, Shruti K. Effects of Anti-depressants on Behavioural consequences following impact accelerated traumatic brain injury in rats: analysis by rodent behavioural test battery. Indian Pharmacological Society Conference, 18-20th December 2008, AIIMS Delhi.

64. Sunita S, Raina A, Mahesh R, Pandey DK. Newer Mechanistic Pathways pertaining to anti-depressant action of escitalopram using acute and chronic animal model of depression and underlying immunological basis of depression. Indian Pharmacological Society Conference, 18-20th December 2008, AIIMS Delhi.

65. Shruti V, Mahesh R, Pandey DK. Anti-depressant and Analgesic Like Activity of 5-HT3 Antagonist - Novel Approach in Treating Co-morbid Depression and Pain. Indian Pharmacological Society Conference, 18-20th December 2008, AIIMS Delhi.

66. Mahesh R, Rajkumar R. Anti-depressant potential of Serotonin Type-3 Antagonists. National Symposium on Challenges in Drug Discovery research: Networking opportunities between Academia and Industries, 7-8 April, 2006 Pilani.

67. Mahesh R, Rajkumar R. Behavioural profiles of ondansetron and meta-chlorophenyl piperazine in mice models of depression. 3rd Singapore International Neuroscience Conference, National Neuroscience Institute, 23 -24th May 2006, Singapore.

68. Mahesh R, Rajkumar R, Perumal VR. Evaluation of Anti-depressant potential of 2-(4-methyl piperzin-1-yl)-1,8-naphthyridine-3- carbonitrile in mice models of depression. Indian Pharmaceutical Congress, 1-3th December 2006, Mumbai.

69. Mahesh R, Rajkumar R, Jain RK, Pareek RP. Prevalence of Gastrointestinal and Respiratory tract disorders during the months of maximum seasonal variation in a population of a semi-urban settlement. Association of Pharmaceutical Teachers of India (APTI) National Convention, 17-18th October 2005, Nagpur.

70. Mahesh R, Rajkumar R, Jain RK, Pareek RP. Analysis of disease prevalence in relation to seasonal variation in a population of a semi-urban settlement – A demographic Study, Indian Pharmaceutical Congress, 2- 4th December 2005, Hyderabad. Indian Pharmaceutical Congress, 2- 4th December 2005, Hyderabad.

71. Mahesh R, Rajkumar R. Recent advances in Central Nervous System. Indian Pharmaceutical Congress, 2- 4th December, 2005 Hyderabad.

72. Bajaj, Shivanshu; Mahesh, Radhakrishnan; Department of Pharmacy, Birla Institute of Technology and Science (BITS), Pilani campus. “Effect of neuromodulators on Depression-induced memory impairment in Swiss Albino Mice”. ISN-MLSU First Neurochemistry School, Department of Pharmaceutical Sciences, Mohanlal Sukhadia University, 2024, Udaipur, Rajasthan, India.

73. Bajaj, Shivanshu; Mahesh Radhakrishnan; Department of Pharmacy, Birla Institute of Technology and Science (BITS), Pilani campus. Depression and Alzheimer’s disease- Shared Pathophysiology. 53^rd Annual Conference of Indian Pharmacological Society, SRM University, 2023, Chennai, India.

74. Bajaj, Shivanshu; Mahesh Radhakrishnan., “Effect of Escitalopram and Galantamine in Combination on Chronic Unpredictable Mild Stress (CUMS) Model of Depression in Swiss Albino Mice with an Emphasis on BDNF, cAMP, Neuroinflammation, and Oxidative Stress” during 4th Science Conclave Cum National Biomedical Research Competitionat ESIC Medical College in collaboration with Society of Young Scientist (SYS), , 2023 AIIMS, Delhi. Best poster award.

75. Bajaj, Shivanshu; Mahesh Radhakrishnan; Department of Pharmacy, Birla Institute of Technology and Science (BITS), Pilani campus. Depression and Alzheimer’s disease- Shared Pathophysiology. 53^rd Annual Conference of Indian Pharmacological Society, SRM University, 2023, Chennai, India.

Integrated first degree

Higher Degree

Doctoral Programmes

WILP

Student Activities

Student Services

Integrated First Degree

Higher Degree

Doctoral Programmes

WILP

Dubai Campus

Give us your feedback

Upload Screenshot

Prof. R. Mahesh

Publications

Book Chapter

Journal Publications

International

National

Conference Publications

International

National

Keep Exploring

Cookie Consent